A Study of SGN-STNV in Advanced Solid Tumors

This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.

The study will include dose escalation (Part A) and dose expansion (Part B), with multiple disease-specific cohorts and a biology cohort in dose expansion. The biology cohort will require additional biopsies. At the completion of dose escalation, up to 5 disease specific expansion cohorts and 1 biology expansion cohort may be activated by the sponsor in consultation with the Safety Monitoring Committee (SMC). Expansion cohorts in Part B will enroll subjects with selected tumors that are eligible for enrollment in Part A. The dose(s) to be examined in Part B will be at or below the maximum tolerated dose and/or the recommended dose determined in Part A. The recommended dose and/or schedule may differ between cohorts.

Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei

NSCLC, Non-Small Cell Lung Cancer, HER2-Negative Breast Cancer, High-Grade Serous Ovarian Cancer, HGSOC, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GEJ Carcinoma, Colorectal Cancer, Seattle Genetics

ORR is defined as the proportion of subjects achieving a partial response (PR) or complete response (CR).

PFS is defined as the time from the start of any study treatment to first documentation of disease progression or to death due to any cause, whichever comes first.

OS is defined as the time from the start of any study treatment to the date of death due to any cause.

DOR is defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression or to death due to any cause, whichever comes first.

Inclusion Criteria: Disease indication Must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies and should have no appropriate standard-of-care therapeutic option. Non-small cell lung cancer (NSCLC) HER2 negative breast cancer Ovarian cancer Cervical cancer Endometrial cancer Esophageal cancer Gastric cancer and GEJ carcinoma Colorectal cancer Exocrine pancreatic adenocarcinoma Appendiceal adenocarcinoma and pseudomyxoma peritonei of unknown origin Participants enrolled in the following study parts should have an appropriate tumor site that satisfies the following criteria: Site has tumor that is not a target lesion and has not been previously irradiated (unless progression has occurred since end of radiotherapy) Site has tumor that is accessible for a minimally invasive biopsy that does not present a significant risk, AND Participant must agree to a biopsy as follows Disease-specific expansion cohorts: pre-treatment biopsy, unless medically infeasible following consultation with the medical monitor Biology expansion cohort: pretreatment biopsy (required) and additional on-treatment biopsy during Cycle 1 (unless medically infeasible following consultation with the medical monitor) Measurable disease per the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) at baseline An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 Adequate renal, hepatic, and hematologic function Exclusion Criteria History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Known active central nervous system metastases Carcinomatous meningitis Previous receipt of monomethylauristatin E (MMAE)-containing drugs Pre-existing neuropathy ≥ Grade 2 per the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 Any uncontrolled ≥ Grade 3 (per the NCI CTCAE, Version 5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of SGN-STNV There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.